PARADIGM: Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6 as First-line Treatment for mCRC With Wild-Type RAS

June 3-7, 2022; Chicago, Illinois
The phase III PARADIGM trial demonstrated superior overall survival with first-line panitumumab vs bevacizumab in combination with mFOLFOX6 in both the left-sided and overall mCRC populations with WT RAS.
Format: Microsoft PowerPoint (.ppt)
File Size: 217 KB
Released: June 9, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

SWOG 1815 trial evaluating the first-line nab-paclitaxel + gemcitabine/cisplatin in advanced biliary tract cancers, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 26, 2023

From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director
Christopher H. Lieu, MD Manish A. Shah, MD
Released: January 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings